140 results on '"Nikiforow, Sarah"'
Search Results
2. Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival
3. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies
4. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
5. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
6. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
7. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
8. Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review
9. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
10. Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
11. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease
12. Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
13. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies
14. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
15. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
16. Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis
17. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
18. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
19. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis
20. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
21. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
22. Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
23. Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft
24. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
25. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide
26. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
27. T Cell Clonal Dynamics Determined by High-Resolution TCR-β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation
28. Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts
29. BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation
30. Identification of germline variants in adults with hemophagocytic lymphohistiocytosis
31. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
32. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
33. Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation
34. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children
35. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
36. Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome
37. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis
38. Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy
39. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma
40. Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease
41. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients
42. A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help
43. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease
44. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease
45. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years
46. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD
47. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial
48. Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
49. A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease
50. Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.